本帖最后由 老马 于 2013-3-13 13:43 编辑 % |4 o. T8 K9 a$ T% i, t
/ ^3 ?/ i% T4 ?# I4 d( a9 d' i健择（吉西他滨）+顺铂+阿瓦斯汀 j$ v7 P( s q1 m3 D; j
Gemzar +Cisplatin + Avastin V0 ]) e; N" V. |4 Z) V
http://annonc.oxfordjournals.org/content/21/9/1804.full
* R% Q+ b( ]2 ~; }& bOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# m- I0 n7 R" h2 ]Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& v: ^) s5 T/ K# j% b5 _: Y5 j' m6 aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 7 _' n( N7 B+ Q' l) ]& d
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 281)
3 p& i. t6 }; I9 m
华为网盘附件：) w& M1 @4 \/ _
【华为网盘】ava.JPG! Z1 s) U @5 E7 _( d
|
egfr19突变，16个月耐药，后续该如何
2023.7月爸爸确诊肺癌晚期，全身多处骨转 脑转，基因检测egfr19突变，单用阿美11个月
跨越十年丨憨叔靶向轮换的感悟及思路
我们在筷子治疗九周年纪念文章《跨越九年丨憨叔靶向轮换传承和发扬 --筷子奥希替尼
建议收藏！肺癌ALK患者靶向药耐药后
作者：闵
ALK突变常被众多病友称为“钻石突变”，不单是由于对应的靶向药价格高昂，更
基因检测出HER2靶点，求靶向药方案
妈妈肺癌肝骨转移脖子疼痛难耐，食欲不振，体质弱不考虑放化疗。求靶向药治疗方案
有了解脾转移的病友吗
肺腺癌1A3期，术后一个月复查，CT平扫脾脏内多发低密度影，增强核磁报脾脏多发转移，
显身卡
